488 related articles for article (PubMed ID: 33140115)
1. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II.
Bukamur H; Alkrekshi A; Katz H; Alsharedi M; Shweihat YR; Munn NJ
South Med J; 2021 Sep; 114(9):614-619. PubMed ID: 34480197
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
Rapoport BL; Shannon VR; Cooksley T; Johnson DB; Anderson L; Blidner AG; Tintinger GR; Anderson R
Front Pharmacol; 2021; 12():743582. PubMed ID: 34675810
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy.
Canale ML; Camerini A; Casolo G; Lilli A; Bisceglia I; Parrini I; Lestuzzi C; Del Meglio J; Puccetti C; Camerini L; Amoroso D; Maurea N
Adv Ther; 2020 Jul; 37(7):3178-3184. PubMed ID: 32436027
[TBL] [Abstract][Full Text] [Related]
6. The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Kooshkaki O; Derakhshani A; Safarpour H; Najafi S; Vahedi P; Brunetti O; Torabi M; Lotfinejad P; Paradiso AV; Racanelli V; Silvestris N; Baradaran B
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708748
[TBL] [Abstract][Full Text] [Related]
7. Severe pulmonary infections complicating nivolumab treatment for lung cancer: a report of two cases.
Inthasot V; Bruyneel M; Muylle I; Ninane V
Acta Clin Belg; 2020 Aug; 75(4):308-310. PubMed ID: 31179880
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
9. Pulmonary adverse events following immune checkpoint inhibitors.
Spagnolo P; Chaudhuri N; Bernardinello N; Karampitsakos T; Sampsonas F; Tzouvelekis A
Curr Opin Pulm Med; 2022 Sep; 28(5):391-398. PubMed ID: 35838354
[TBL] [Abstract][Full Text] [Related]
10. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
11. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
[TBL] [Abstract][Full Text] [Related]
12. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
13. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view.
Memon H; Patel BM
Life Sci; 2019 Sep; 233():116713. PubMed ID: 31386875
[TBL] [Abstract][Full Text] [Related]
15. Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series.
Braga Neto MB; Ramos GP; Loftus EV; Faubion WA; Raffals LE
Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1285-1287.e1. PubMed ID: 32565289
[TBL] [Abstract][Full Text] [Related]
16. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient.
Fragulidis G; Pantiora E; Michalaki V; Kontis E; Primetis E; Vezakis A; Polydorou A
J Oncol Pharm Pract; 2019 Mar; 25(2):487-491. PubMed ID: 29067858
[TBL] [Abstract][Full Text] [Related]
17. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
18. Nivolumab-associated Stevens-Johnson syndrome in a patient with lung cancer.
Gracia-Cazaña T; Padgett E; Calderero V; Oncins R
Dermatol Online J; 2021 Mar; 27(3):. PubMed ID: 33865285
[TBL] [Abstract][Full Text] [Related]
19. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma.
Safa H; Bhosale P; Weissferdt A; Oliva ICG
Immunotherapy; 2020 Apr; 12(5):293-298. PubMed ID: 32295435
[TBL] [Abstract][Full Text] [Related]
20. Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis.
Kashiwada T; Minegishi Y; Saito Y; Kato T; Atsumi K; Seike M; Kubota K; Terasaki Y; Gemma A
J Nippon Med Sch; 2019; 86(1):43-47. PubMed ID: 30918156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
